Description

The fund's advisor endeavors to allocate nearly all of its assets to the specific securities and depositary receipts comprising its benchmark index. This index is crafted to reflect the performance of a modified equal-weighted collection of Chinese companies, each playing a direct role in the expansion of China's pharmaceutical and biotechnology sectors.